Relutrigine

Name: Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Clinical presentation - signs and symptoms
Published: 2026-09-14T15:39:06-04:00

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted in early 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Clinical presentation - signs and symptoms

1 evidence topic · 2 sources

Neurological symptoms: seizures, encephalopathy, and intellectual disability

“SCN8A-related epilepsy with encephalopathy is a condition characterized by recurrent seizures (epilepsy), abnormal brain function (encephalopathy), and intellectual disability.” (opens the source at this quote in a new tab)